The annual general meeting in Prostatype Genomics AB (publ), corp. reg. no 556726-0285 (the “Company”) was held on 1 June 2023 whereby the shareholders resolved on the following matters.
Annual report and results
The annual general meeting adopted the income statement and the balance sheet for the financial year 2022 and resolved, in accordance with the board of directors’ proposal, that the result according to the approved income statement should be transferred to a new account. No dividends are to be paid.
Discharge from liability
The general meeting granted the board of directors as well as the managing director discharge from liability for the management of the Company’s business for the financial year 2022.
Remuneration to the board of directors and the auditor
The annual general meeting resolved that the chairman shall receive remuneration with SEK 160,000 and that every other board member shall receive remuneration with SEK 80,000, unless the member in question is not prevented from receiving such remuneration due to the applicable guidelines of the member’s employer.
The annual general meeting resolved that the auditor shall receive remuneration according to approved invoice.
Election of board of directors and auditor
The annual general meeting resolved that the board of directors shall consist of five (5) directors without any deputy directors.
The general meeting resolved, for the time until the end of the next annual general meeting, to re-elect Anders Lundberg, Michael Häggman, Håkan Englund and Mattias Prage as members of the board of directors. Further, Henrik Nilsson was elected as new member of the board. Karlheinz Schmelig was not available for re-election. Anders Lundberg was elected as the chairman of the board of directors.
It was resolved to re-elect Grant Thornton Sweden AB as auditor, with Joakim Söderin as chief auditor, for the time until the end of the next annual general meeting.
Nomination committee for the annual general meeting 2024
The annual general meeting resolved that the Company, in advance of the annual general meeting in 2024, shall establish a nomination committee. It was resolved that the members of the nomination committee shall be appointed by instruction from the chairman of the board of directors to the three largest shareholders in the Company on 30 September 2023 to appoint a representative each that, together with the chairman of the board of directors, shall constitute the nomination committee.
Authorization to the board of directors to resolve on new issues
The annual general meeting authorized the board of directors to, on one or several occasions for the time until the next annual general meeting, resolve on issues of shares, warrants and/or convertible instruments (or combinations thereof, so-called units) with an amount corresponding to a maximum of 15 percent of the Company’s registered share capital at the time the authorization is used for the first time. If the board exercises the authorization, this may also be done with a deviation from the shareholders' preferential rights and/or with provisions on non-cash or set-off. An issue in accordance with the authorization shall be made at fair market value.
All resolutions at the general meeting were made unanimously.
For further information, please contact:
Fredrik Persson, CEO of Prostatype Genomics AB
Tel: +46 (0) 73 049 77 01, e-mail: email@example.com